CCR5
C-C chemokine receptor type 5
Also known as: CC-CKR-5, CCR5_HUMAN, CD195, CKR-5, CKR5, CMKBR5, IDDM22
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P51681
- Gene
- CCR5
- Ensembl
- ENSG00000160791
- Chromosome
- 3
- Canonical length
- 352 aa
- Protein class
- CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins
OverviewNCBI Gene
This gene encodes a member of the beta chemokine receptor family, which is predicted to be a seven transmembrane protein similar to G protein-coupled receptors. This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. Defective alleles of this gene have been associated with the HIV infection resistance. The ligands of this receptor include monocyte chemoattractant protein 2 (MCP-2), macrophage inflammatory protein 1 alpha (MIP-1 alpha), macrophage inflammatory protein 1 beta (MIP-1 beta) and regulated on activation normal T expressed and secreted protein (RANTES). Expression of this gene was also detected in a promyeloblastic cell line, suggesting that this protein may play a role in granulocyte lineage proliferation and differentiation. This gene is located at the chemokine receptor gene cluster region. An allelic polymorphism in this gene results in both functional and non-functional alleles; the reference genome represents the functional allele. Two transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Jul 2015]
Canonical amino-acid sequenceUniProt
352 residues, UniProt reviewed canonical sequence.
>P51681|CCR5
1 MDYQVSSPIY DINYYTSEPC QKINVKQIAA RLLPPLYSLV FIFGFVGNML VILILINCKR
61 LKSMTDIYLL NLAISDLFFL LTVPFWAHYA AAQWDFGNTM CQLLTGLYFI GFFSGIFFII
121 LLTIDRYLAV VHAVFALKAR TVTFGVVTSV ITWVVAVFAS LPGIIFTRSQ KEGLHYTCSS
181 HFPYSQYQFW KNFQTLKIVI LGLVLPLLVM VICYSGILKT LLRCRNEKKR HRAVRLIFTI
241 MIVYFLFWAP YNIVLLLNTF QEFFGLNNCS SSNRLDQAMQ VTETLGMTHC CINPIIYAFV
301 GEKFRNYLLV FFQKHIAKRF CKCCSIFQQE APERASSVYT RSTGEQEISV GLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CCR5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 7
- Mean surface accessibility (rSASA)
- 0.33
- Highest tissue expression
- 15 nTPM
Expression across tissuesHPA
Tissue
- appendix: 15 nTPM
- lymph node: 14 nTPM
- spleen: 9.1 nTPM
- tonsil: 9.1 nTPM
- lung: 7.1 nTPM
- stomach: 6.6 nTPM
Single-cell type
- cdc: 22 nCPM
- t-cells: 19 nCPM
- pdcs: 16 nCPM
- monocytes: 15 nCPM
- macrophages: 14 nCPM
- nk-cells: 3.8 nCPM
Immune cell
- MAIT T-cell: 41 nTPM
- memory CD8 T-cell: 16 nTPM
- basophil: 12 nTPM
- gdT-cell: 11 nTPM
- myeloid DC: 9.7 nTPM
- plasmacytoid DC: 9.2 nTPM
Brain region
- white matter: 4.3 nTPM
- medulla oblongata: 2.7 nTPM
- thalamus: 2.2 nTPM
- pons: 2.1 nTPM
- spinal cord: 2 nTPM
- choroid plexus: 1.8 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about CCR5.
Disease | AllUniProt
Conditions CCR5 is implicated in, by any mechanism.
- Type 1 diabetes mellitus 22 (T1D22) MIM:612522
Disease | AutoantibodyPubMed
Conditions in which antibodies against CCR5 are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for CCR5 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
9 publications
- Papillomavirus-like particle vaccines.
2001 · J Natl Cancer Inst Monogr · RCR 1.2 · 53 citations - Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression.
2006 · Blood · RCR 1 · 47 citations - Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus.
2004 · J Virol · RCR 0.9 · 42 citations - Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy.
2005 · J Virol · RCR 0.6 · 28 citations - Effects of immunization with CCR5-based cycloimmunogen on simian/HIVSF162P3 challenge.
2006 · J Immunol · RCR 0.6 · 24 citations
Show 4 more
- Induction of HIV-blocking anti-CCR5 IgA in Peyers's patches without histopathological alterations.
2014 · J Virol · RCR 0.3 · 9 citations - Transient chemokine receptor blockade does not prevent, but may accelerate type 1 diabetes in prediabetic NOD mice.
2006 · Horm Metab Res · RCR 0.2 · 9 citations - The Abrogation of Phosphorylation Plays a Relevant Role in the CCR5 Signalosome Formation with Natural Antibodies to CCR5.
2017 · Viruses · RCR 0.2 · 5 citations - Circular CCR5 peptide conjugates and uses thereof (WO2008074895).
2009 · Expert Opin Ther Pat · RCR 0.1 · 6 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.93
- gnomAD pLI
- 0
- gnomAD missense Z
- -1.45
- DepMap mean gene effect
- 0.02
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- apoptotic process
- calcium ion transport
- calcium-mediated signaling
- cell chemotaxis
- cell surface receptor signaling pathway
- cell-cell signaling
- cellular defense response
- cellular response to lipopolysaccharide
- chemotaxis
- dendritic cell chemotaxis
- G protein-coupled receptor signaling pathway
- immune response
- inflammatory response
- MAPK cascade
- negative regulation of macrophage apoptotic process
- positive regulation of cytosolic calcium ion concentration
- release of sequestered calcium ion into cytosol by sarcoplasmic reticulum
- response to cholesterol
- signaling
Molecular functions
- actin binding
- C-C chemokine binding
- C-C chemokine receptor activity
- chemokine (C-C motif) ligand 5 binding
- chemokine receptor activity
- coreceptor activity
- identical protein binding
- phosphatidylinositol-4,5-bisphosphate phospholipase C activity
- virus receptor activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of CCR5 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CCR5 as an antibody target. Whether an autoantibody or antibody against CCR5 could matter depends on whether native CCR5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CCR5 is annotated at the cell surface, where native CCR5 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label CCR5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...